SLC5A2 and atrial fibrillation: Weight loss reduce progression of AF.81The GLP-agonist semaglutide reduces the risk of AF by 42% regardless of BMI in a meta-analysis of RCTs.108Weight loss after initiation of Sodium–Glucose Cotransporter 2 (SGLT-2) inhibitor reduced the risk of AF